(Q42957646)

11 November 2017

title

Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain (English)

1 reference

11 November 2017

1 reference

Thea Bismo Strøm

1

1 reference

11 November 2017

Øystein L Holla

2

1 reference

11 November 2017

Kristian Tveten

3

1 reference

11 November 2017

Jamie Cameron

4

1 reference

11 November 2017

Knut Erik Berge

5

1 reference

11 November 2017

Trond P Leren

6

1 reference

11 November 2017

language of work or name

1 reference

9 June 2010

1 reference

Molecular Genetics and Metabolism

11 November 2017

published in

1 reference

11 November 2017

volume

101

1 reference

11 November 2017

issue

1

1 reference

11 November 2017

page(s)

76-80

1 reference

Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

Retention of mutant low density lipoprotein receptor in endoplasmic reticulum (ER) leads to ER stress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

4-Phenylbutyrate restores the functionality of a misfolded mutant low-density lipoprotein receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

The effect of bafilomycin A1 and protease inhibitors on the degradation and recycling of a Class 5-mutant LDLR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

Low-density-lipoprotein receptors in human fibroblasts are not degraded in lysosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

Pathways and mechanisms of endocytic recycling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

Molecules internalized by clathrin-independent endocytosis are delivered to endosomes containing transferrin receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.003

10.1016/J.YMGME.2010.05.003

7 January 2021

Identifiers

DOI

1 reference

11 November 2017

1 reference